Hyundai Bioscience Co (XKRX:048410) Total Liabilities : ₩7,320 Mil (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Total Liabilities?

Hyundai Bioscience Co's Total Liabilities for the quarter that ended in Mar. 2024 was ₩7,320 Mil.

Hyundai Bioscience Co's quarterly Total Liabilities increased from Sep. 2023 (₩7,476.94 Mil) to Dec. 2023 (₩7,520.75 Mil) but then declined from Dec. 2023 (₩7,520.75 Mil) to Mar. 2024 (₩7,319.83 Mil).

Hyundai Bioscience Co's annual Total Liabilities declined from Dec. 2021 (₩18,957.44 Mil) to Dec. 2022 (₩9,091.42 Mil) and declined from Dec. 2022 (₩9,091.42 Mil) to Dec. 2023 (₩7,520.75 Mil).

Hyundai Bioscience Co Total Liabilities Historical Data

The historical data trend for Hyundai Bioscience Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Total Liabilities Chart

Hyundai Bioscience Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

16,462.66

41,403.37

18,957.44

9,091.42

7,520.75

Hyundai Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															8,588.74	6,875.81	7,476.94	7,520.75	7,319.83

Hyundai Bioscience Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hyundai Bioscience Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6946.76	+	(32.432	+	541.557
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7,521

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	52791.761	-	45271.012
	=	7,521

Hyundai Bioscience Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6716.943	+	(24.159	+	526.557
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	52.175)
	=	7,320

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	53730.675	-	46410.841
	=	7,320

Hyundai Bioscience Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Bioscience Co (XKRX:048410) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR

Website

http://www.hyundaibioscience.com

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines